Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1188-2024Class III

In-vitro diagnostic kits: (1) Abbott Vysis MDM2 / CEP 12 FISH Probe Kit, REF 01N15-010; (2) Abbott Vysis LSI...

Abbott Molecular, Inc. / initiated 2024-02-01 / Open, Classified / root cause: manufacturing process

Abbott Molecular, Inc. began a recall of In-vitro diagnostic kits: (1) Abbott Vysis MDM2 / CEP 12 FISH Probe Kit, REF 01N15-010; (2) Abbott Vysis LSI D13S319 (13q14.3) SpectrumOrange Probe, REF... on . FDA classified it as Class III and gives the reason as "Products that were intended for export only which were not approved or registered in accordance with U.S. specifications were shipped to U.S. customers". As of , the recall status on record is Open, Classified, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-1188-2024
Classification
Class III
Status
Open, Classified
Initiated
Posted
Recalling firm
Abbott Molecular, Inc.
Product
In-vitro diagnostic kits: (1) Abbott Vysis MDM2 / CEP 12 FISH Probe Kit, REF 01N15-010; (2) Abbott Vysis LSI D13S319 (13q14.3) SpectrumOrange Probe, REF 01N34-020;
Product code
OYU Dna-Probe Kit, Human Chromosome
Reason for recall
Products that were intended for export only which were not approved or registered in accordance with U.S. specifications were shipped to U.S. customers.
Root cause tag
manufacturing process
FDA root cause
Process control
Action
The recalling firm issued letters dated and issued on 2/1/2024 via FedEx priority overnight express mail. The letter explained the background, potential impact, and necessary actions to be taken and contained an appendix listing Impacted Abbott Products and an appendix listing CE products and similar US products. The actions to be taken were to destroy all remaining inventory of the impacted products and contact their local Abbott representative for replacements. If the product has been forwarded to other laboratories, the consignee is requested to inform them of the recall and have them take the necessary actions. The letter states that laboratories should follow internal procedures in regard to a lookback of results and a lookback should be considered if results have been released that are tied to performance claims. A Customer Reply Form was enclosed to acknowledge receipt of the letter. The consignee was to record the amount of affected product that was destroyed.
Quantity in commerce
16 kits
Distribution
US Nationwide distribution in the states of AL, CA, IL, MA, MD, MN, NY, and PA.
Product codes and lots
(1) REF 01N15-010 - GTIN 00884999035362, Lot #381146, Exp. 2024-05-05; #381870, Exp. 2024-05-05; #382179 Exp. 2024-05-05; #387021, Exp. 2024-08-01; #528081, exp. 2023-11-16; (2) REF 01N34-020 - GTIN 00884999000766, Lot #522756, Exp. 2023-06-21.

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1188-2024
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1188-2024Class IIIOngoingVoluntary: Firm initiated
Z-1189-2024Class IIIOngoingVoluntary: Firm initiated
Z-1190-2024Class IIIOngoingVoluntary: Firm initiated